{"id":"plavix-with-astrix","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-3","effect":"Diarrhea"},{"rate":"1-2","effect":"Rash"},{"rate":"<0.1","effect":"Thrombotic thrombocytopenic purpura (TTP)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a thienopyridine antiplatelet agent that irreversibly binds to the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. This mechanism reduces the formation of platelet-rich thrombi in arterial circulation. The combination with aspirin (Astrix) provides dual antiplatelet therapy for enhanced antithrombotic effect.","oneSentence":"Plavix (clopidogrel) inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, reducing thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:17.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina, NSTEMI, STEMI)"},{"name":"Secondary prevention of atherothrombotic events in patients with established peripheral arterial disease, previous myocardial infarction, or ischemic stroke"}]},"trialDetails":[{"nctId":"NCT04407312","phase":"PHASE4","title":"Cilostazol and Endothelial Progenitor Cell","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2016-01-01","conditions":"Myocardial Infarction, Acute","enrollment":60},{"nctId":"NCT01192724","phase":"PHASE4","title":"Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03","conditions":"Coronary Artery Disease","enrollment":630},{"nctId":"NCT01763749","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin","status":"COMPLETED","sponsor":"Seoul St. Mary's Hospital","startDate":"2012-10","conditions":"Coronary Artery Disease","enrollment":91},{"nctId":"NCT02294643","phase":"PHASE3","title":"Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-04","conditions":"Coronary Artery Disease, Diabetes Mellitus, Renal Insufficiency, Chronic","enrollment":220},{"nctId":"NCT01765452","phase":"PHASE4","title":"Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2012-10","conditions":"Coronary Artery Disease","enrollment":285}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Plavix with Astrix","genericName":"Plavix with Astrix","companyName":"Seoul St. Mary's Hospital","companyId":"seoul-st-mary-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Plavix (clopidogrel) inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, reducing thrombotic events. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Secondary prevention of atherothrombotic events in patients with established peripheral arterial disease, previous myocardial infarction, or ischemic stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}